Difference in the Lubrication Efficiency of Bovine and Vegetable-Derived Magnesium Stearate During Tabletting
- 292 Downloads
The purpose of this work was to evaluate and compare the functionality of bovine fatty acids-derived (MgSt-B) and vegetable fatty acids-derived (MgSt-V) magnesium stearate powders when used for the lubrication of granules prepared by high-shear (HSG) and fluid bed (FBG) wet granulation methods. The work included evaluation of tablet compression and ejection forces during tabletting and dissolution testing of the compressed tablets. Granules prepared by both granulation methods required significantly lower ejection force (p < 0.01) when lubricated with the MgSt-V powder as compared to those lubricated with the MgSt-B powder. Granules prepared by the HSG method and lubricated with the MgSt-V powder also required significantly lower compression force (p < 0.01) to produce tablets of similar weight and hardness as compared to those lubricated with the MgSt-B powder. The dissolution profiles were not affected by these differences and were the same for tablets prepared by same granulation method and lubricated with either magnesium stearate powder. The results indicate significant differences (p < 0.01) between lubrication efficiency of the MgSt-B and the MgSt-V powders and emphasize the importance of functionality testing of the MgSt powders to understand the impact of these differences.
Key wordscharacterization fluid bed granulation functionality testing high-shear granulation lubricant efficiency magnesium stearate
The authors gratefully acknowledge Robbe C. Lyon, Christopher D. Ellison, Agnes A Nguyenpho and Rakhi B. Shah for their technical suggestions, contribution, and help with some of these studies.
- 1.United States Food and Drug Administration Guidance Document. Changes to an approved NDA or ANDA. 2004. http://www.fda.gov/cder/guidance/3516fnl.htm (accessed 07/25/2006).
- 2.United States Food and Drug Administration Guidance Document. Immediate-release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation 1995. http://www.fda.gov/cder/guidance/cmc5.pdf (accessed 07/25/2006).
- 7.United States Pharmacopeia 30/National Formulary 25. 2008. The US Pharmacopeial Convention, Inc. Rockville, MD. http://www.USP.org (accessed 02/05/2008).
- 9.Brauner JS, Bradby S, Chow BC, Lindauer RF, White PA. Magnesium stearate-specific surface area and hydration states of 29 commercial samples. PF. 1997;23:889–922.Google Scholar